Changing the Standard
of Palliative Care
Creating Best-In-Class Treatment Options
As a leader in Cancer Comfort Care, RAMTherapeutics is proud to offer hope and relief to those facing the toughest challenges of cancer treatment. Learn more about our innovative approach and discover how Triamdocaine™ is changing the standard of palliative care for patients around the world.
About RAMTherapeutics
At RAMTherapeutics, we are committed to developing innovative solutions for patients suffering from severe oral mucositis (SOM), a painful and often debilitating side effect of radiation and chemotherapy treatments. As part of our Cancer Comfort Care mission, our breakthrough medication, Triamdocaine™, is revolutionizing the way cancer patients experience comfort during their journey to recovery.
RAMTherapeutics is a clinical-stage pharmaceutical company dedicated to creating best-in-class treatment options for patients experiencing oral mucositis due to cancer therapy. Our flagship medication, Triamdocaine™, is specifically designed to provide fast, long-lasting relief from the painful lesions caused by radiation and chemotherapy. By targeting the oral mucosal tissues directly, this cutting-edge treatment not only eases discomfort but also supports faster healing, allowing patients to focus on their health and well-being.
There is currently no drug approved to prevent or treat SOM in cancer patients.
Expanding Horizons
Innovating Supportive Cancer Care
Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of tumors and cancer. According to the Centers for Disease Control and Protection (CDC), each year, about 650,000 cancer patients receive chemotherapy and 575,000 receive radiation treatment in an outpatient oncology clinic in the United States alone. Severe Oral Mucositis (SOM) is a common debilitating side effect of radiation treatment in HNC patients. SOM, defined by the World Health Organization as Grade 3 or 4 OM, occurs in 60 to 80 percent of HNC patients who receive radiation therapy. Importantly, SOM may result in interruptions in radiation treatment, which can compromise the otherwise good prognosis for tumor control in many of these patients. In addition, patients suffer significant pain, may develop serious infections, and may be unable to eat solid food or even drink liquids. Further, the costs of managing these side effects are substantial, particularly when hospitalization and/or surgical placement of PEG tubes to maintain nutrition and hydration is required. RAMTherapeutics is a clinical stage pharmaceutical company with a goal of developing a best-in-class treatment option for patients suffering from oral mucositis as a result of cancer treatment.
Key Elements
Triamdocaine will address the following:
- Pain and Discomfort: One of the primary concerns with mucositis is the severe pain it causes, especially in the oral and esophageal regions. This pain can be so intense that it interferes with a patient’s ability to eat, drink, and even speak, leading to a significant reduction in quality of life.
- Risk of Infection: The sores and ulcers characteristic of mucositis provide a potential entry point for bacteria and other pathogens. Since chemotherapy and radiation often weaken the immune system, patients with mucositis are at a higher risk of developing infections, which can sometimes be severe and systemic.
- Nutritional Complications: Due to pain and difficulty in swallowing, patients often struggle with adequate nutrition and hydration. This can lead to weight loss, malnutrition, and dehydration, further complicating the recovery process and overall health.
- Treatment Interruptions: In severe cases, mucositis can lead to the need to modify or interrupt cancer treatment. This can affect the efficacy of the cancer treatment plan, potentially impacting the overall prognosis of the patient.
- Emotional and Psychological Impact: Dealing with the symptoms of mucositis can be emotionally draining for patients. It can lead to feelings of frustration, sadness, and anxiety, contributing to an overall decline in mental health.
- Increased Healthcare Costs: The management of mucositis, including pain control, nutritional support, and treatment of infections, can lead to increased healthcare costs. This financial burden can add to the stress experienced by patients and their families.
